The FDA has granted Adherex Technologies orphan-drug designation for its cancer drug eniluracil. The designation was granted for the use of eniluracil in combination with fluoropyrimidines for the treatment of hepatocellular cancer. Adherex in-licensed eniluracil from GlaxoSmithKline in July and is developing the drug to improve the therapeutic value and effectiveness of 5-fluorouracil, one of the world's most commonly used chemotherapies.